Corient Private Wealth LP Takes $2.61 Million Position in Omnicell, Inc. $OMCL

Corient Private Wealth LP acquired a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) in the second quarter, HoldingsChannel reports. The fund acquired 62,810 shares of the company’s stock, valued at approximately $2,608,000.

Several other large investors have also made changes to their positions in OMCL. Raymond James Financial Inc. acquired a new position in Omnicell in the second quarter valued at $26,000. Versant Capital Management Inc increased its stake in Omnicell by 38.7% during the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after acquiring an additional 294 shares during the last quarter. Clearstead Advisors LLC raised its holdings in shares of Omnicell by 12,180.0% in the 4th quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after purchasing an additional 1,218 shares during the period. Kemnay Advisory Services Inc. purchased a new position in shares of Omnicell in the 4th quarter worth about $58,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Omnicell by 1,708.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after purchasing an additional 1,264 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $34.71 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. Omnicell, Inc. has a 1-year low of $29.06 and a 1-year high of $55.00. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of 41.32, a PEG ratio of 0.87 and a beta of 0.97. The business has a 50-day moving average of $39.55 and a 200-day moving average of $39.29.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.47 by $0.47. The business had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The company’s revenue was up 7.4% on a year-over-year basis. During the same period last year, the business posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, equities analysts anticipate that Omnicell, Inc. will post 1.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OMCL has been the subject of a number of research reports. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Zacks Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Piper Sandler reiterated an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. KeyCorp reissued an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Finally, Wells Fargo & Company cut their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $57.86.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.